The ONTOZRY® Live Forum webinars introduced healthcare professionals across the UK to a new treatment option for adult patients with drug-resistant focal-onset seizures.
Epileptologists, Neurologists and Epilepsy Specialist Nurses joined to hear our expert panels discuss the current management of drug-resistant epilepsy as well as the latest ONTOZRY® data. The panels were led by Dr Rhys Thomas, Prof. Ley Sander and Consultant Epilepsy Specialist Nurse Phil Tittensor, who each added their valuable opinion on what the arrival of ONTOZRY® could mean for eligible patients.
If you were unable to attend a webinar, or want a refresh on what you heard, you can now watch the session recap videos below, which are split into three core sections.
1. ONTOZRY® Summary of Product Characteristics.
*This event was developed and funded by Arvelle Therapeutics (part of Angelini Pharma Company) for UK Healthcare Professionals.
UK11412P | April 2022